Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.

ABSTRACT:

Background

Real-world clinical data to support the use of casirivimab-imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab-imdevimab treatment of mild to moderate COVID-19.

Methods

A retrospective cohort of 696 patients who received casirivimab-imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion.

Findings

The median age of the antibody-treated cohort was 63 years (interquartile range, 52-71); 45·5% were ≥65 yea

SUBMITTER: Razonable RR 

PROVIDER: S-EPMC8404031 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature